Portfolio Holdings Detail for ISIN IE000G4PH2B1
Stock Name / Fund iShares S&P 500 Paris-Aligned Climate UCITS ETF USD Dist
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker UPAD(USD) LSE
ETF Ticker UPAD.L(GBP) LSE

Holdings detail for REGN

Stock Name	Regeneron Pharmaceuticals Inc
Ticker	REGN(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US75886F1075
LEI	549300RCBFWIRX3HYQ56

Show aggregate REGN holdings

News associated with REGN

Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria: (RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
Peek Under The Hood: JEPQ Has 10% Upside: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-08 08:26:56
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages: Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and three […] - 2025-08-26 02:16:48
LABU, INCY, UTHR, REGN: ETF Outflow Alert: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Regeneron Pharmaceuticals (NASDAQ:REGN) versus Cadrenal Therapeutics (NASDAQ:CVKD) Head-To-Head Analysis: Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings. Volatility and Risk Regeneron Pharmaceuticals has a beta […] - 2025-08-20 02:22:48
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00: Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target reduced by Truist Financial from $940.00 to $812.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of several other reports. The Goldman Sachs Group dropped their price target on […] - 2025-08-14 03:00:52
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Blair William & Co. IL: Blair William & Co. IL lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.2% in the 1st quarter, Holdings Channel reports. The fund owned 1,282 shares of the biopharmaceutical company’s stock after buying an additional 27 shares during the period. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth […] - 2025-08-11 06:26:50
Harbour Investments Inc. Sells 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Harbour Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Harbour Investments Inc.’s holdings in […] - 2025-08-07 09:40:47
We Did The Math SPYX Can Go To $58: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 08:58:54
409 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Arkadios Wealth Advisors: Arkadios Wealth Advisors purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 409 shares of the biopharmaceutical company’s stock, valued at approximately $259,000. Several other institutional investors and hedge funds also […] - 2025-08-07 05:38:53
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says: Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target upped by stock analysts at BMO Capital Markets from $600.00 to $640.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 12.30% from […] - 2025-08-06 03:12:48
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $828.86 Consensus Target Price from Brokerages: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have assigned a buy recommendation and two […] - 2025-08-04 02:59:01
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 19:31:54
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:40:40
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:35:36
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:02:25
Nasdaq 100 Movers: MRVL, REGN: In early trading on Friday, shares of Regeneron Pharmaceuticals, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Regeneron Pharmaceuticals, has lost about 20.7% of its value. And the worst performing Nasdaq 100 co - 2025-08-01 11:30:09
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Choreo LLC: Choreo LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,746 shares of the biopharmaceutical company’s stock after acquiring an additional 32 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals […] - 2025-07-24 07:22:56
Crestwood Advisors Group LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Crestwood Advisors Group LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467 shares of the biopharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Crestwood Advisors Group […] - 2025-07-24 05:47:12
Kestra Private Wealth Services LLC Has $1.31 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Kestra Private Wealth Services LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,058 shares of the biopharmaceutical company’s stock after buying an additional 132 shares during the quarter. […] - 2025-07-23 07:50:58
Larson Financial Group LLC Has $34,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Larson Financial Group LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 34.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53 shares of the biopharmaceutical company’s stock after selling 28 shares during the quarter. Larson […] - 2025-07-23 06:30:53
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alps Advisors Inc.: Alps Advisors Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 71.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 530 shares of the biopharmaceutical company’s stock after purchasing an additional 220 shares during the quarter. Alps Advisors Inc.’s […] - 2025-07-17 05:50:54
Stratos Wealth Partners LTD. Sells 115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Stratos Wealth Partners LTD. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Stratos Wealth Partners […] - 2025-07-16 04:58:54
Allworth Financial LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Allworth Financial LP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 14.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 821 shares of the biopharmaceutical company’s stock after selling 137 shares during the period. Allworth Financial […] - 2025-07-15 08:20:00
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $584.00: Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target increased by UBS Group from $560.00 to $584.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on REGN. BMO Capital Markets reduced their price objective on Regeneron […] - 2025-07-14 03:30:48
Brown Advisory Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Brown Advisory Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,269 shares of the biopharmaceutical company’s stock after selling 247 shares during the quarter. Brown Advisory Inc.’s […] - 2025-07-13 05:54:54
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Cut by D.A. Davidson & CO.: D.A. Davidson & CO. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 732 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. D.A. […] - 2025-07-11 05:32:52
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $813.57: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued […] - 2025-07-10 03:07:00
DAVENPORT & Co LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): DAVENPORT & Co LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 427 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. A number of other institutional […] - 2025-07-09 05:11:22
Bessemer Group Inc. Sells 3,860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Bessemer Group Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 76.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,218 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the period. Bessemer Group […] - 2025-07-01 05:46:52

iShares S&P 500 Paris-Aligned Climate UCITS ETF USD Dist REGN holdings

Date	Number of REGN Shares Held	Base Market Value of REGN Shares	Local Market Value of REGN Shares	Change in REGN Shares Held	Change in REGN Base Value	Current Price per REGN Share Held	Previous Price per REGN Share Held
2025-09-18 (Thursday)	4,281	USD 2,563,078	USD 2,563,078	12	USD 108,147	USD 598.71	USD 575.06
2025-09-16 (Tuesday)	4,269	USD 2,454,931	USD 2,454,931	0	USD 10,544	USD 575.06	USD 572.59
2025-09-15 (Monday)	4,269	USD 2,444,387	USD 2,444,387	0	USD 53,747	USD 572.59	USD 560
2025-09-12 (Friday)	4,269	USD 2,390,640	USD 2,390,640	0	USD -35,006	USD 560	USD 568.2
2025-09-11 (Thursday)	4,269	USD 2,425,646	USD 2,425,646	0	USD 52,808	USD 568.2	USD 555.83
2025-09-10 (Wednesday)	4,269	USD 2,372,838	USD 2,372,838	-24	USD -16,345	USD 555.83	USD 556.53
2025-09-09 (Tuesday)	4,293	USD 2,389,183	USD 2,389,183	0	USD -8,200	USD 556.53	USD 558.44
2025-09-08 (Monday)	4,293	USD 2,397,383	USD 2,397,383

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of REGN by Blackrock for IE000G4PH2B1

Show aggregate share trades of REGN

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-09-18 BUY 12 598.710* 642.33
2025-09-10 SELL -24 555.830* 644.56 Profit of 15,469 on sale
2025-08-20 BUY 60 591.010* 646.48
2025-08-15 SELL -24 580.410* 647.79 Profit of 15,547 on sale
2025-07-21 SELL -48 545.530* 653.06 Profit of 31,347 on sale
2025-07-17 BUY 12 550.000* 654.48
2025-07-15 SELL -84 547.960* 655.91 Profit of 55,096 on sale
2025-07-09 SELL -24 552.580* 656.61 Profit of 15,759 on sale
2025-07-03 SELL -24 547.360* 659.70 Profit of 15,833 on sale
2025-07-02 SELL -120 547.740* 660.49 Profit of 79,258 on sale
2025-06-30 SELL -348 525.000* 661.44 Profit of 230,181 on sale
2025-06-13 SELL -72 529.240* 671.07 Profit of 48,317 on sale
2025-06-12 SELL -54 521.840* 672.20 Profit of 36,299 on sale
2025-06-11 SELL -162 518.600* 673.37 Profit of 109,086 on sale
2025-06-10 SELL -198 523.530* 674.52 Profit of 133,556 on sale
2025-06-05 BUY 54 483.070* 678.69
2025-05-19 SELL -9 596.540* 691.67 Profit of 6,225 on sale
2025-05-13 BUY 27 574.160* 695.69
2025-05-02 BUY 36 605.610* 704.33
2025-05-01 SELL -45 590.000* 705.45 Profit of 31,745 on sale
2025-04-28 SELL -153 610.860* 708.86 Profit of 108,456 on sale
2025-04-16 BUY 36 549.280* 720.49
2025-04-08 BUY 54 556.810* 731.78
2025-04-07 SELL -144 572.780* 733.67 Profit of 105,649 on sale
2025-04-04 SELL -27 573.450* 735.60 Profit of 19,861 on sale
2025-03-28 SELL -450 637.360* 741.03 Profit of 333,461 on sale
2025-03-27 SELL -18 635.830* 742.37 Profit of 13,363 on sale
2025-03-24 SELL -18 661.000* 746.26 Profit of 13,433 on sale
2025-03-21 SELL -461 658.480* 747.45 Profit of 344,575 on sale
2025-03-18 SELL -240 664.960* 750.87 Profit of 180,208 on sale
2025-03-14 SELL -70 666.870* 753.13 Profit of 52,719 on sale
2025-03-13 SELL -10 680.610* 754.20 Profit of 7,542 on sale
2025-03-12 BUY 100 689.500* 755.16
2025-03-11 BUY 130 718.160* 755.73
2025-03-07 BUY 60 707.510* 756.65
2025-03-05 BUY 130 687.150* 757.75
2025-02-26 BUY 20 706.940* 763.27
2025-02-12 BUY 20 663.860* 778.87
2025-02-05 BUY 40 716.720* 787.93
2025-01-02 BUY 425 715.190* 818.70
2024-12-09 SELL -9 788.000* 820.98 Profit of 7,389 on sale
2024-12-03 SELL -18 749.570* 829.66 Profit of 14,934 on sale
2024-12-02 BUY 9 762.340* 832.25
2024-11-29 BUY 18 750.220* 835.53
2024-11-27 BUY 45 754.870* 842.54
2024-11-26 BUY 54 753.030* 846.61
2024-11-22 BUY 18 738.000* 856.90
2024-11-19 BUY 18 744.600* 876.79
2024-11-18 BUY 27 762.000* 883.97
2024-11-12 BUY 9 821.000* 888.17
2024-11-05 BUY 90 829.430* 911.23
2024-10-31 BUY 36 838.200* 939.11
2024-10-30 BUY 135 922.790* 941.44
2024-10-21 BUY 18 968.500* 0.00
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-09-18	BUY	12	598.710*	642.33
2025-09-10	SELL	-24	555.830*	644.56 Profit of 15,469 on sale
2025-08-20	BUY	60	591.010*	646.48
2025-08-15	SELL	-24	580.410*	647.79 Profit of 15,547 on sale
2025-07-21	SELL	-48	545.530*	653.06 Profit of 31,347 on sale
2025-07-17	BUY	12	550.000*	654.48
2025-07-15	SELL	-84	547.960*	655.91 Profit of 55,096 on sale
2025-07-09	SELL	-24	552.580*	656.61 Profit of 15,759 on sale
2025-07-03	SELL	-24	547.360*	659.70 Profit of 15,833 on sale
2025-07-02	SELL	-120	547.740*	660.49 Profit of 79,258 on sale
2025-06-30	SELL	-348	525.000*	661.44 Profit of 230,181 on sale
2025-06-13	SELL	-72	529.240*	671.07 Profit of 48,317 on sale
2025-06-12	SELL	-54	521.840*	672.20 Profit of 36,299 on sale
2025-06-11	SELL	-162	518.600*	673.37 Profit of 109,086 on sale
2025-06-10	SELL	-198	523.530*	674.52 Profit of 133,556 on sale
2025-06-05	BUY	54	483.070*	678.69
2025-05-19	SELL	-9	596.540*	691.67 Profit of 6,225 on sale
2025-05-13	BUY	27	574.160*	695.69
2025-05-02	BUY	36	605.610*	704.33
2025-05-01	SELL	-45	590.000*	705.45 Profit of 31,745 on sale
2025-04-28	SELL	-153	610.860*	708.86 Profit of 108,456 on sale
2025-04-16	BUY	36	549.280*	720.49
2025-04-08	BUY	54	556.810*	731.78
2025-04-07	SELL	-144	572.780*	733.67 Profit of 105,649 on sale
2025-04-04	SELL	-27	573.450*	735.60 Profit of 19,861 on sale
2025-03-28	SELL	-450	637.360*	741.03 Profit of 333,461 on sale
2025-03-27	SELL	-18	635.830*	742.37 Profit of 13,363 on sale
2025-03-24	SELL	-18	661.000*	746.26 Profit of 13,433 on sale
2025-03-21	SELL	-461	658.480*	747.45 Profit of 344,575 on sale
2025-03-18	SELL	-240	664.960*	750.87 Profit of 180,208 on sale
2025-03-14	SELL	-70	666.870*	753.13 Profit of 52,719 on sale
2025-03-13	SELL	-10	680.610*	754.20 Profit of 7,542 on sale
2025-03-12	BUY	100	689.500*	755.16
2025-03-11	BUY	130	718.160*	755.73
2025-03-07	BUY	60	707.510*	756.65
2025-03-05	BUY	130	687.150*	757.75
2025-02-26	BUY	20	706.940*	763.27
2025-02-12	BUY	20	663.860*	778.87
2025-02-05	BUY	40	716.720*	787.93
2025-01-02	BUY	425	715.190*	818.70
2024-12-09	SELL	-9	788.000*	820.98 Profit of 7,389 on sale
2024-12-03	SELL	-18	749.570*	829.66 Profit of 14,934 on sale
2024-12-02	BUY	9	762.340*	832.25
2024-11-29	BUY	18	750.220*	835.53
2024-11-27	BUY	45	754.870*	842.54
2024-11-26	BUY	54	753.030*	846.61
2024-11-22	BUY	18	738.000*	856.90
2024-11-19	BUY	18	744.600*	876.79
2024-11-18	BUY	27	762.000*	883.97
2024-11-12	BUY	9	821.000*	888.17
2024-11-05	BUY	90	829.430*	911.23
2024-10-31	BUY	36	838.200*	939.11
2024-10-30	BUY	135	922.790*	941.44
2024-10-21	BUY	18	968.500*	0.00

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of REGN

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	208,659	1,635	312,812	66.7%
2025-09-18	236,485	3,679	387,519	61.0%
2025-09-17	229,191	716	370,895	61.8%
2025-09-16	173,632	584	271,020	64.1%
2025-09-15	204,491	251	334,496	61.1%
2025-09-12	117,504	33	222,760	52.7%
2025-09-11	125,478	3,137	286,516	43.8%
2025-09-10	195,068	481	339,885	57.4%
2025-09-09	129,168	994	274,520	47.1%
2025-09-08	250,895	396	527,062	47.6%
2025-09-05	170,149	290	289,566	58.8%
2025-09-04	188,227	2,103	360,619	52.2%
2025-09-03	185,679	344	438,111	42.4%
2025-09-02	191,954	138	476,288	40.3%
2025-08-29	133,226	685	236,726	56.3%
2025-08-28	116,560	2,177	256,675	45.4%
2025-08-27	113,719	465	243,836	46.6%
2025-08-26	210,376	450	400,199	52.6%
2025-08-25	149,130	68	363,377	41.0%
2025-08-22	211,822	3,244	701,770	30.2%
2025-08-21	257,492	3,416	446,439	57.7%
2025-08-20	327,738	572	559,133	58.6%
2025-08-19	118,472	2,191	324,311	36.5%
2025-08-18	146,282	388	277,909	52.6%
2025-08-15	209,923	3,375	441,752	47.5%
2025-08-14	157,569	3,623	429,327	36.7%
2025-08-13	111,342	233	362,786	30.7%
2025-08-12	117,647	171	310,775	37.9%
2025-08-11	129,513	2,676	284,757	45.5%
2025-08-08	128,559	1,038	431,841	29.8%
2025-08-07	166,648	1,560	352,877	47.2%
2025-08-06	176,311	624	397,089	44.4%
2025-08-05	154,257	115	353,744	43.6%
2025-08-04	200,758	1,913	409,897	49.0%
2025-08-01	349,775	3,745	728,720	48.0%
2025-07-31	222,350	476	549,344	40.5%
2025-07-30	106,839	1,689	231,761	46.1%
2025-07-29	149,359	276	292,667	51.0%
2025-07-28	103,687	1,380	245,287	42.3%
2025-07-25	103,783	556	259,069	40.1%
2025-07-24	156,974	2,397	291,677	53.8%
2025-07-23	168,734	1,708	355,372	47.5%
2025-07-22	116,324	617	304,880	38.2%
2025-07-21	98,482	900	250,107	39.4%
2025-07-18	183,174	1,051	391,909	46.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares S&P 500 Paris-Aligned Climate UCITS ETF USD Dist
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	UPAD(USD) LSE
ETF Ticker	UPAD.L(GBP) LSE